AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators

11 Mar, 2021

AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
Photo by Asaf Gazit on Unsplash

– AgomAb Therapeutics N.V. announced today the closing of a $74m Series B financing round led by Redmile Group, with participation from Cormorant Asset Management.
– All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures.
– The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies.
– The capital will also support further growth of the company’s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases.

Biotechnology Europe Health Care Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: